Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03222817 · ClinicalTrials.gov registry record · NA
HPV Self-Sampling for Cervical Cancer Screening Among Transgender Men and Transmasculine Individuals
A NA study, sponsored by University of Miami.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT03222817 is a NA study that has completed, run by University of Miami. The registered enrollment target is 10 participants.
The verdict
NCT03222817, a NA study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The proposed study will examine the implementation of a Human Papillomavirus (HPV) self-sampling intervention for unscreened and under-screened transgender men and transmasculine individuals living in South Florida. The study will enroll participants to receive this cervical cancer screening intervention in community venues. The purpose of this study is to pilot the self-sampler for feasibility and acceptability within this underserved population.
Interventions
- BEHAVIORAL HPV self-sampling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-05-12 |
| Est. Completion | 2018-10-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03222817
The ClinicalTrials.gov registry entry for NCT03222817 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HPV self-sampling is the first listed.
NCT03222817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03222817 about?
NCT03222817 is a clinical study titled "HPV Self-Sampling for Cervical Cancer Screening Among Transgender Men and Transmasculine Individuals". The proposed study will examine the implementation of a Human Papillomavirus (HPV) self-sampling intervention for unscreened and under-screened transgender men and transmasculine individuals living in South Florida. The study will enroll participants to receive this cervical cancer screening interve...
What is the current status of trial NCT03222817?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2018-05-12. Estimated completion is 2018-10-17.
What interventions are being tested in trial NCT03222817?
The interventions under investigation include: HPV self-sampling (BEHAVIORAL).
Who is sponsoring clinical trial NCT03222817?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.